[{"data":1,"prerenderedAt":256},["ShallowReactive",2],{"$f3giw9ykftpjps":3},{"schema":4,"slug":5,"series":6,"series_slug":7,"name":8,"year":9,"therapeutic_area":10,"generated_at":11,"counts":12,"top_targets":20,"top_modalities":53,"top_diseases":78,"top_companies":108,"key_results":135,"trends":217,"previous_editions":226,"comparison":230,"highlighted_classes":255},1,"ectrims-2026","ECTRIMS","ectrims","ECTRIMS Congress 2026",2026,"Neurology","2026-11-05T22:19:09Z",{"abstracts":13,"drug_linked":14,"companies":15,"by_phase":16},1959,606,68,{"Phase 1":17,"Phase 1\u002F2":4,"Phase 2":18,"Phase 4":17,"Phase 3":19},12,26,61,[21,25,29,33,35,38,41,43,47,50],{"name":22,"count":23,"share":24},"CD20",226,37,{"name":26,"count":27,"share":28},"ADA",57,9,{"name":30,"count":31,"share":32},"ITGA4",45,7,{"name":34,"count":31,"share":32},"α4β7",{"name":36,"count":37,"share":32},"α4β1",44,{"name":39,"count":18,"share":40},"BTK",4,{"name":42,"count":18,"share":40},"CD19",{"name":44,"count":45,"share":46},"S1PR5",21,3,{"name":48,"count":49,"share":46},"IL-6R",19,{"name":51,"count":52,"share":46},"GR",17,[54,57,61,65,68,70,74,76],{"name":55,"count":56,"share":27},"Monoclonal antibodies",345,{"name":58,"count":59,"share":60},"Small molecules",286,47,{"name":62,"count":63,"share":64},"Non-antibody therapeutic proteins",38,6,{"name":66,"count":67,"share":40},"Peptides",24,{"name":69,"count":45,"share":46},"Cell therapies",{"name":71,"count":72,"share":73},"Blood, tissue and cell-derived products",13,2,{"name":75,"count":72,"share":73},"Radiopharmaceuticals",{"name":77,"count":32,"share":4},"Bispecific antibodies",[79,83,87,90,93,97,99,101,103,105],{"name":80,"count":81,"share":82},"multiple sclerosis (MS)",493,81,{"name":84,"count":85,"share":86},"Neuromyelitis Optica Spectrum Disorder (NMOSD)",60,10,{"name":88,"count":89,"share":32},"secondary-progressive multiple sclerosis (SPMS)",42,{"name":91,"count":92,"share":64},"primary progressive multiple sclerosis (PPMS)",36,{"name":94,"count":95,"share":96},"myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)",31,5,{"name":98,"count":49,"share":46},"autoimmune encephalomyelitis (AEM)",{"name":100,"count":86,"share":73},"progressive multifocal leukoencephalopathy (PML)",{"name":102,"count":28,"share":4},"demyelinating disease",{"name":104,"count":64,"share":4},"optic neuritis (ON)",{"name":106,"count":73,"share":107},"autoimmune colitis",0,[109,112,116,119,121,123,126,129,131,133],{"name":110,"count":111,"share":18},"Genentech",160,{"name":113,"count":114,"share":115},"Novartis",65,11,{"name":117,"count":118,"share":86},"Merck KGaA",58,{"name":120,"count":27,"share":28},"Biogen",{"name":122,"count":45,"share":46},"Sanofi",{"name":124,"count":125,"share":46},"Chugai Pharmaceutical",18,{"name":127,"count":128,"share":73},"Amgen",14,{"name":130,"count":128,"share":73},"Bristol Myers Squibb",{"name":132,"count":72,"share":73},"Johnson & Johnson",{"name":134,"count":72,"share":73},"Pfizer",[136,144,150,157,163,169,176,182,188,196,203,211],{"title":137,"drug":138,"company":140,"phase":141,"disease":94,"finding":142,"url":143},"Efficacy and safety of tocilizumab in patients with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (TOMATO): a randomised, multicentre, open-label, phase 3 trial",{"name":139,"slug":139},"tocilizumab",null,"Phase 3","Relapses occurred in 6 (9%) participants receiving tocilizumab plus prednisone treatment and 18 (53%) receiving prednisone treatment alone (hazard ratio 0.13 [95% CI 0.05-0.33], p\u003C0.0001).","https:\u002F\u002Fdistribute.congrex.com\u002Ffrom.storage?image=0_gHiw_79U0XUHI8aIvppaois9bkxlhs5n2wXk3LtAGHau27Jv8IgjOzQDwm8AXv0",{"title":145,"drug":146,"company":113,"phase":141,"disease":80,"finding":148,"url":149},"Ofatumumab Versus Physicians’ Choice of Disease Modifying Therapy in Treatment-Naive People Living With Relapsing Multiple Sclerosis: Final Efficacy Results of the Phase 3b STHENOS study",{"name":147,"slug":147},"ofatumumab","NEDA-3 was achieved by 80.2% (69\u002F86) vs 43.7% (31\u002F71) participants with OMB vs cFL-DMT (odds ratio: 5.02, p\u003C0.001).","https:\u002F\u002Fdistribute.congrex.com\u002Ffrom.storage?image=0_gHiw_79U0XUHI8aIvppYyW_a1Nm5JLCYdGt8WOHzrEONsZNHEh1uNiBVCG61v50",{"title":151,"drug":152,"company":154,"phase":141,"disease":94,"finding":155,"url":156},"Time to Relapse in Patients With Relapsing MOGAD Treated With Satralizumab: Results From the Phase 3 METEOROID Study",{"name":153,"slug":153},"satralizumab","Roche","When the time to first adjudicated relapse or first use of rescue therapy was analyzed, satralizumab reduced the risk of relapse by 63% compared with placebo (HR: 0.37, 95% CI: 0.19–0.73; p=0.0025).","https:\u002F\u002Fdistribute.congrex.com\u002Ffrom.storage?image=0_gHiw_79U0XUHI8aIvppR5n4_PBQfcwQDavQVmTySgqRlRXqv0unBSpMn71TRCz0",{"title":158,"drug":159,"company":140,"phase":141,"disease":84,"finding":161,"url":162},"Anti-CD38 monoclonal antibody daratumumab for the treatment of aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorder (DAWN): a multicenter, double-blind, randomized phase 3 clinical trial",{"name":160,"slug":160},"daratumumab","Relapses occurred in 17 patients (19%) receiving daratumumab and in 27 (60%) receiving placebo (hazard ratio, 0.26; 95% confidence interval [CI], 0.14 to 0.47; p\u003C0.0001).","https:\u002F\u002Fdistribute.congrex.com\u002Ffrom.storage?image=0_gHiw_79U0XUHI8aIvppbAY6gv0ZcrpiWETZ0UvpmGp0XUhSuWC3EYMSrWZG7OD0",{"title":164,"drug":165,"company":154,"phase":141,"disease":80,"finding":167,"url":168},"No Evidence of Disease Activity With Fenebrutinib vs Teriflunomide in Relapsing Multiple Sclerosis: Results From the Phase III FENhance 1 and 2 Trials",{"name":166,"slug":166},"fenebrutinib","FEN significantly reduced risk of disease activity vs TFM per NEDA-3 (HR, 0.30; 95% CI 0.25-0.35; P\u003C0.001).","https:\u002F\u002Fdistribute.congrex.com\u002Ffrom.storage?image=0_gHiw_79U0XUHI8aIvppXQnniLG-FrHgqy7l2emWEYXFfuSycjmZTZANYcEPvON0",{"title":170,"drug":171,"company":173,"phase":141,"disease":80,"finding":174,"url":175},"Seven-Year Safety and Efficacy Outcomes for Ublituximab treatment in Relapsing MS",{"name":172,"slug":172},"ublituximab","TG Therapeutics","CDP 24 at year 7 was 11.7% in UBL-UBL vs 17.4% in TER-UBL patients [HR (95% CI): 0.65 (0.46, 0.92); P=0.015].","https:\u002F\u002Fdistribute.congrex.com\u002Ffrom.storage?image=0_gHiw_79U0XUHI8aIvppV74JP4Gu8tHl-dhXHz-q3TBAlRkTqENFBXXHPsunDgE0",{"title":177,"drug":178,"company":140,"phase":141,"disease":80,"finding":180,"url":181},"Impact of Ponesimod on Progression Independent of Relapse Activity in Relapsing MS: OPTIMUM and Long-Term Extension Results.",{"name":179,"slug":179},"ponesimod","During the core period, at week 108, ponesimod reduced the risk of disability accumulation versus teriflunomide for 12w cCDA (23.4% vs 31.1%; HR 0.75 [0.59–0.95]).","https:\u002F\u002Fdistribute.congrex.com\u002Ffrom.storage?image=0_gHiw_79U0XUHI8aIvppWIIZe64Fx97RDw9QYB3PVsb7jA7kS2wtU8oFpCzK_o30",{"title":183,"drug":184,"company":140,"phase":141,"disease":80,"finding":186,"url":187},"Rituximab versus Ocrelizumab in Newly Diagnosed Relapsing Multiple Sclerosis: Results from the OVERLORD-MS Randomized Noninferiority Trial",{"name":185,"slug":185},"rituximab","Serious adverse events were similar and occurred in 6.8% and 7.1%, respectively, whereas infections were more frequent with rituximab (81.8% vs. 69.0%).","https:\u002F\u002Fdistribute.congrex.com\u002Ffrom.storage?image=0_gHiw_79U0XUHI8aIvppRIK2mbqV9T21VgqmubZtNnxHixMWPPsDBZXLe_Y8hZM0",{"title":189,"drug":190,"company":193,"phase":141,"disease":84,"finding":194,"url":195},"One-year efficacy and safety of divozilimab in patients with neuromyelitis optica spectrum disorders: results from the phase III AQUARELLE study",{"name":191,"slug":192},"Divozilimab","divozilimab","Biocad","In the indirect comparison, divozilimab was associated with a significant reduction in risk of relapse versus historical placebo (weighted HR 0.108; 95% CI 0.036-0.324; p\u003C0.001).","https:\u002F\u002Fdistribute.congrex.com\u002Ffrom.storage?image=0_gHiw_79U0XUHI8aIvppVsqvjc98VudSnezEoEH2xqcNymV34G5jeLb8HS-ycrn0",{"title":197,"drug":198,"company":140,"phase":200,"disease":80,"finding":201,"url":202},"Low-Dose Ketamine Infusion for Multiple Sclerosis Fatigue: Results of the INKLING-MS Randomized Phase 2 Trial",{"name":199,"slug":199},"ketamine","Phase 2","An ≥8-point MFIS response occurred in 71.2% on ketamine compared with 37.8% on midazolam (adjusted odds ratio, 4.55; 95% CI, 1.91–10.87; p\u003C0.001).","https:\u002F\u002Fdistribute.congrex.com\u002Ffrom.storage?image=0_gHiw_79U0XUHI8aIvppVaQ6vRP2kwyMDfdKkdMW8IBL9z-8-fxgYq3pdLNpLZC0",{"title":204,"drug":205,"company":208,"phase":200,"disease":80,"finding":209,"url":210},"Evaluation of Disability Outcomes from the Open-Label Extension of CALLIPER: A Phase 2 Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis",{"name":206,"slug":207},"vidofludimus calcium","vidofludimus-calcium","Immunic","CDI events occurred more frequently in the VidoCa-VidoCa group versus PBO-VidoCa (HR: 2.84, p=0.008).","https:\u002F\u002Fdistribute.congrex.com\u002Ffrom.storage?image=0_gHiw_79U0XUHI8aIvppWxplzCwvc9IUNktNIRYFtuCionTd1BPgRHUcZl4Y6wk0",{"title":212,"drug":213,"company":140,"phase":200,"disease":84,"finding":215,"url":216},"Efficacy and Safety of Eculizumab for Acute Attack of Neuromyelitis Optica Spectrum Disorder (EASE-NMO): a Multi-Center, Phase 2 Trial",{"name":214,"slug":214},"eculizumab","For key secondary endpoints in the ITT analysis, the IVMP+Ecu group showed greater reduction in OSIS (2.55 vs. 1.12, mean difference, 1.42; 95% CI, 0.48-2.36; P\u003C0.005) and EDSS (0.99 vs. 0.36, mean difference, 0.63; 95% CI, 0.24-1.01; P\u003C0.005) compared to IVMP at Day 28.","https:\u002F\u002Fdistribute.congrex.com\u002Ffrom.storage?image=0_gHiw_79U0XUHI8aIvppXIfxW_Idb_EW4Y59tItZ3XD6xy-8q3nPfs-fS5LLdoY0",{"summary":218,"bullets":220},[219],"Small molecules accounted for 47% of drug-linked abstracts, up from 40% in 2025. Monoclonal antibodies, the most frequent modality, accounted for 57% of drug-linked abstracts, up from 53% in 2025. Blood, tissue and cell-derived products (2%) were new to the top modalities compared with 2025.",[221,222,223,224,225],"BTK (4% of drug-linked abstracts) was new to the top targets compared with 2025.","CD20 was the most frequent target (37%).","Multiple sclerosis (MS) was the most frequent disease (81%).","Genentech had the largest company share (26%).","Non-antibody therapeutic proteins accounted for 6% of drug-linked abstracts, up from 2% in 2025.",[227],{"year":228,"abstracts":229},2025,2015,{"previous_year":228,"abstracts":231,"targets":233,"modalities":245,"new_in_top_targets":253,"new_in_top_modalities":254},{"previous":229,"current":13,"change_pct":46,"direction":232},"fell",[234,238,239,241,243],{"name":22,"count":23,"share":24,"previous_count":235,"previous_share":236,"direction":237},199,34,"rose",{"name":39,"count":18,"share":40,"previous_count":86,"previous_share":73,"direction":237},{"name":26,"count":27,"share":28,"previous_count":240,"previous_share":17,"direction":232},70,{"name":44,"count":45,"share":46,"previous_count":242,"previous_share":64,"direction":232},35,{"name":30,"count":31,"share":32,"previous_count":244,"previous_share":28,"direction":232},54,[246,249,252],{"name":58,"count":59,"share":60,"previous_count":247,"previous_share":248,"direction":237},234,40,{"name":55,"count":56,"share":27,"previous_count":250,"previous_share":251,"direction":237},309,53,{"name":62,"count":63,"share":64,"previous_count":72,"previous_share":73,"direction":237},[39],[71],[],1793970603089]